Series A brings AMD drug developer Ophthotech $36mm
Ophthotech (eye therapeutics) has raised $36mm in its Series A financing. SV Life Sciences led the round and was joined by other investors including HBM BioVentures and Novo AS.
- Antisense, Oligonucleotides
- Venture Financing
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.